The best oncology drug launch in history

Revolution Medicines’ Rasonque earned $198 million in its first five weeks, a strong debut for a non-degrading molecular glue drug.
Rasonque momentum builds as glue degraders advance in immunology

Daraxonrasib (Rasonque) combination data at ESMO 2026, a second Phase 2 for Monte Rosa’s VAV1 glue degrader, and new AI tools for molecular glue research.